Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 1/20 | 0.55 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.49 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.46 |
| ▸ | PRMT5 | O14744 | 2/20 | 0.45 |
| ▸ | DPP4 | P27487 | 1/20 | 0.45 |
| ▸ | ATM | Q13315 | 2/20 | 0.43 |
| ▸ | AHCY | P23526 | 3/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | DRD2 | P14416 | 2/20 | 0.41 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.41 |
| ▸ | METTL3 | Q86U44 | 1/20 | 0.40 |
| ▸ | PDE8B | O95263 | 1/20 | 0.39 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11969272 | 0.97 | OPRD1 (0.52) | KDM1AOPRD1HRH3PRMT5DPP4 | |
| SCHEMBL4877870 | 0.81 | ATM (0.42) | KDM1AOPRD1ATMDRD2PDE8B | |
| SCHEMBL11969310 | 0.81 | OPRD1 (0.48) | KDM1AOPRD1HRH3ATMAHCY | |
| SCHEMBL20012324 | 0.80 | NAMPT (0.40) | KDM1AOPRD1PRMT5DPP4MEN1 | |
| SCHEMBL20012293 | 0.80 | NAMPT (0.40) | KDM1AOPRD1DPP4MEN1KMT2A | |
| SCHEMBL13202546 | 0.79 | ATM (0.46) | KDM1AOPRD1ATMCHEK2PDE8B | |
| SCHEMBL11969315 | 0.79 | OPRD1 (0.48) | KDM1AOPRD1ATMAHCYMEN1 | |
| SCHEMBL11969463 | 0.78 | KDM1A (0.46) | KDM1AOPRD1PRMT5ATMAHCY | |
| SCHEMBL23029738 | 0.78 | ATM (0.47) | KDM1AOPRD1ATMCHEK2PDE8B | |
| SCHEMBL20812496 | 0.78 | KDM1A (0.45) | KDM1AOPRD1ATMMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3970723-A1 | AMINOINDANE COMPOUNDS FOR USE IN TREATING UROLOGICAL PAIN | Asana BioSciences, LLC (US) | 2022-03-23 | — | — | EP | disclosed |
| EP-3363437-B1 | AMINOINDANE COMPOUNDS AND USE THEREOF IN TREATING PAIN | ENDO PHARMACEUTICALS SOLUTIONS (US) | 2021-07-28 | — | — | EP | disclosed |
| EP-3363437-B1 | AMINOINDANE COMPOUNDS AND USE THEREOF IN TREATING PAIN | ENDO PHARMACEUTICALS SOLUTIONS (US) | 2021-07-28 | — | — | EP | disclosed |
| EP-3363437-A1 | AMINOINDANE COMPOUNDS AND USE THEREOF IN TREATING PAIN | Endo Pharmaceuticals Solutions Inc. (US) | 2018-08-22 | — | — | EP | disclosed |
| EP-2675787-B1 | AMINOINDANE COMPOUNDS AND USE THEREOF IN TREATING PAIN | ENDO PHARMACEUTICALS INC (US) | 2018-03-28 | — | — | EP | disclosed |
| EP-2675787-B1 | AMINOINDANE COMPOUNDS AND USE THEREOF IN TREATING PAIN | ENDO PHARMACEUTICALS INC (US) | 2018-03-28 | — | — | EP | disclosed |
| US-9375423-B2 | Use of aminoindane compounds in treating overactive bladder and interstitial cystitis | ASANA BIOSCIENCES, LLC (US) | 2016-06-28 | — | — | US | disclosed |
| US-9375423-B2 | Use of aminoindane compounds in treating overactive bladder and interstitial cystitis | ASANA BIOSCIENCES, LLC (US) | 2016-06-28 | — | — | US | disclosed |
| US-20150290182-A1 | USE OF AMINOINDANE COMPOUNDS IN TREATING OVERACTIVE BLADDER AND INTERSTITIAL CYSTITIS | ASANA BIOSCIENCES, LLC (US) | 2015-10-15 | — | — | US | disclosed |
| US-20150290182-A1 | USE OF AMINOINDANE COMPOUNDS IN TREATING OVERACTIVE BLADDER AND INTERSTITIAL CYSTITIS | ASANA BIOSCIENCES, LLC (US) | 2015-10-15 | — | — | US | disclosed |
| US-8865741-B2 | Aminoindane compounds and use thereof in treating pain | ASANA BIOSCIENCES, LLC (US) | 2014-10-21 | — | — | US | disclosed |
| US-8865741-B2 | Aminoindane compounds and use thereof in treating pain | ASANA BIOSCIENCES, LLC (US) | 2014-10-21 | — | — | US | disclosed |
| US-20140051702-A1 | Use of Aminoindane Compounds in Treating Overactive Bladder and Interstitial Cystitis | ENDO PHARMACEUTICALS INC. (US) | 2014-02-20 | — | — | US | disclosed |
| US-20140051702-A1 | Use of Aminoindane Compounds in Treating Overactive Bladder and Interstitial Cystitis | ENDO PHARMACEUTICALS INC. (US) | 2014-02-20 | — | — | US | disclosed |
| WO-2014028675-A1 | USE OF AMINOINDANE COMPOUNDS IN TREATING OVERACTIVE BLADDER AND INTERSTITIAL CYSTITIS | ENDO PHARMACEUTICALS INC. (US) | 2014-02-20 | — | — | WO | disclosed |
| WO-2014028675-A1 | USE OF AMINOINDANE COMPOUNDS IN TREATING OVERACTIVE BLADDER AND INTERSTITIAL CYSTITIS | ENDO PHARMACEUTICALS INC. (US) | 2014-02-20 | — | — | WO | disclosed |
| EP-2675787-A1 | AMINOINDANE COMPOUNDS AND USE THEREOF IN TREATING PAIN | Endo Pharmaceuticals Inc. (US) | 2013-12-25 | — | — | EP | disclosed |
| WO-2012112969-A1 | AMINOINDANE COMPOUNDS AND USE THEREOF IN TREATING PAIN | ENDO PHARMACEUTICALS INC. (US) | 2012-08-23 | — | — | WO | disclosed |
| US-20120214809-A1 | Aminoindane Compounds and Use Thereof in Treating Pain | Libertas Bio, Inc. | 2012-08-23 | — | — | US | disclosed |
| US-20120214809-A1 | Aminoindane Compounds and Use Thereof in Treating Pain | Libertas Bio, Inc. | 2012-08-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120214809-A1 | Aminoindane Compounds and Use Thereof in Treating Pain | TRPA1, TRPV1, TRPV2 | KDM1A 717/4885OPRD1 47/4885HRH3 247/4885 |
| US-20140051702-A1 | Use of Aminoindane Compounds in Treating Overactive Bladder and Interstitial Cystitis | IDO1, IDO2, SLC1A2 | KDM1A 2847/4885OPRD1 51/4885HRH3 400/4885 |
| US-20150290182-A1 | USE OF AMINOINDANE COMPOUNDS IN TREATING OVERACTIVE BLADDER AND INTERSTITIAL CYSTITIS | IDO1, IDO2, SLC1A2 | KDM1A 2847/4885OPRD1 51/4885HRH3 400/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.